



डा. राजीव सिंह रघुवंशी  
सचिव-सह-वैज्ञानिक निदेशक

Dr. Rajeev Singh Raghuvanshi  
Secretary-cum-Scientific Director

F. No. T.11013/02/2018-AR&D

Date: 10<sup>th</sup> March 2021

**NOTICE**


**Subject: Omission of Monographs of 'Lorcaserin Hydrochloride Hemihydrate' and 'Lorcaserin Tablets' from the Indian Pharmacopoeia-regarding.**

Based on the safety clinical trial and possible risk of cancer associated with Lorcaserin, manufacturer has voluntarily withdrawn the said product from the US market.

2. Subsequently, to safe guard the public health, manufacturer has also voluntarily withdrawn the distributed product from the Indian market.

3. In view of above, monographs of 'Lorcaserin Hydrochloride Hemihydrate' and 'Lorcaserin Tablets' are omitted from the Indian Pharmacopoeia (IP) 2018.

4. All concerned are requested to bring it to the notice of all authorities under their control for the compliance.

  
(Dr Rajeev Singh Raghuvanshi)

To,

1. The Drugs Controller General (India)
2. CDSCO Zonal Offices
3. All State Drug Controllers
4. Members of the Scientific Body of IPC
5. Members of Sub-Committees of the Scientific Body of IPC
6. Directors of Drugs Testing Laboratories
7. Government Analysts
8. IDMA/OPPI/BDMA/FOPE/FSSAI/Small Scale Industry Associations

